Bart Ploeger, PhD

Job title:
Chief Scientific Officer
Organization:
LAP&P Consultants BV
Contributions:
Published Contributions:
Showing disease modifying effects requires an objective method for analyzing UPDRS versus time curves
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
20 Oct 2009 04:46 AM EST
The different views of Drs. Grove and Schwarzschild on whether or not slopes of the UPDRS versus time curves in the ADAGIO and ELLDOPA trial show disease modifying effects demonstrates that the ... 
Better ways to understand drug effects in Parkinson's disease
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
2 Oct 2009 05:55 AM EST
This is the second reported delayed start trial with an inconclusive result. The first trial, TEMPO, was with the same drug (Parkinson Study Group, 2004a ) and since then some lessons ... 
Responses: 1